中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2010年
1期
48-49
,共2页
胡正委%靳凤烁%孙中义%徐光辉
鬍正委%靳鳳爍%孫中義%徐光輝
호정위%근봉삭%손중의%서광휘
慢性前列腺炎%抗生素%靶向经皮给药
慢性前列腺炎%抗生素%靶嚮經皮給藥
만성전렬선염%항생소%파향경피급약
Chronic prostatitis%Antibiotics%Transdermal drug targeting delivery
目的 研究抗生素(左氧氟沙星+药物敏感内抗生素)超声电导靶向经皮给药治疗慢性前列腺炎的疗效.方法 采用同种类抗生素超声电导经皮靶向给药(观察组)和传统全身静脉用药(对照组),对比治疗前后症状、体征、前列腺液,并观察不良反应及半年复发率,分析两组疗效.结果 观察组总有效率为100%,半年复发率为13.15%;对照组总有效率为86.15%,半年复发率为40.44%.两组疗效及半年复发率对比差异均有统计学意义(P<0.01).结论 抗生素超声电导靶向经皮给药与传统静脉给药治疗慢性前列腺炎相比,疗效更高,复发率低,不良反应小,是一种安全、有效的治疗方法 .
目的 研究抗生素(左氧氟沙星+藥物敏感內抗生素)超聲電導靶嚮經皮給藥治療慢性前列腺炎的療效.方法 採用同種類抗生素超聲電導經皮靶嚮給藥(觀察組)和傳統全身靜脈用藥(對照組),對比治療前後癥狀、體徵、前列腺液,併觀察不良反應及半年複髮率,分析兩組療效.結果 觀察組總有效率為100%,半年複髮率為13.15%;對照組總有效率為86.15%,半年複髮率為40.44%.兩組療效及半年複髮率對比差異均有統計學意義(P<0.01).結論 抗生素超聲電導靶嚮經皮給藥與傳統靜脈給藥治療慢性前列腺炎相比,療效更高,複髮率低,不良反應小,是一種安全、有效的治療方法 .
목적 연구항생소(좌양불사성+약물민감내항생소)초성전도파향경피급약치료만성전렬선염적료효.방법 채용동충류항생소초성전도경피파향급약(관찰조)화전통전신정맥용약(대조조),대비치료전후증상、체정、전렬선액,병관찰불량반응급반년복발솔,분석량조료효.결과 관찰조총유효솔위100%,반년복발솔위13.15%;대조조총유효솔위86.15%,반년복발솔위40.44%.량조료효급반년복발솔대비차이균유통계학의의(P<0.01).결론 항생소초성전도파향경피급약여전통정맥급약치료만성전렬선염상비,료효경고,복발솔저,불량반응소,시일충안전、유효적치료방법 .
Objective To research the therapeutic effect of ultrasonic transdermal antibiotic (Levofloxacin+Drug sensitivity in antibiotics) targeting delivery in chronic prostatitis patients. Methods With comparison between the ultrasonic transdermal antibiotic targeting delivery (observation group) and conventional general intravenous drug therapy (control group) of using the same types of antibiotics, to observe the symptoms and signs before and after treatment, to determine the efficacy by checking prostatic fluid, and to observe adverse reactions and the six months relapse rate. Results With analysis of effects of the two total effective rate as 86.15%, the six months recurrence rate as 40.44%. There were significantly differents (P<0.01). Conclusions Compared with conventional intravenous administration, ultrasonic transdermal antibiotic targeting delivery in chronic prostatitis patients is a safe and effective treatment, with higher efficacy, lower relapse rate and smaller adverse reactions.